Marshall Wace, LLP Zymeworks Inc. Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $191,797 - $306,398	-39,792 Reduced 64.46%	21,943 $117,000
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $370,410 - $1.05 Million	61,735 New	61,735 $405,000
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $263,224 - $379,738	-9,933 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$29.83 - $56.81 $296,301 - $564,293	9,933 New	9,933 $314,000
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $710,301 - $998,453	-18,157 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $1.54 Million - $2.45 Million	-52,605 Reduced 74.34%	18,157 $846,000
Q2 2020 Aug 13, 2020	BUY	$33.67 - $40.0 $2.38 Million - $2.83 Million	70,762 New	70,762 $2.55 Million
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $19,933 - $40,885	-821 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$24.84 - $45.46 $140,644 - $257,394	-5,662 Reduced 87.34%	821 $37,000
Q3 2019 Nov 14, 2019	BUY	$22.78 - $29.08 $147,682 - $188,525	6,483 New	6,483 $161,000
Q2 2019 Aug 14, 2019	SELL	$15.0 - $22.49 $835,800 - $1.25 Million	-55,720 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$14.02 - $16.74 $781,194 - $932,752	55,720 New	55,720 $902,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $901M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.